Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.

Slideshare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.

3.
The introduction of the first phosphodiesterase (PDE)-5
inhibitor, sildenafil (Viagra), in 1998 revolutionized the
treatment of the major sexual dysfunction affecting men
as erectile disorder.
They are also being misused as recreational drugs that
are believed to enhance sexual performance.These drugs
have been used by more than 20 million men, if not
more, around the world.
 Sildenafil was originally developed to treat angina
pectoris but later on was recognized as novel treatment
option for impotence.To date, sildenafil has been the
most extensively studied PDE-5 inhibitor.
Introduction

4.
The development of sildenafil provided important
information about the physiology of erection.
Sexual stimulation causes the release of the
neurotransmitter nitric oxide (NO), which increases the
synthesis of cyclic guanosine monophosphate
(cGMP), causing smooth muscle relaxation in the corpus
cavernosum that allows blood to flow into the penis and
that results in turgidity.
The concentration of cGMP is regulated by the enzyme
PDE-5, which, when inhibited, allows cGMP to increase
and enhance erectile function. Because sexual stimulation
is required to cause the release of NO, PDE-5 inhibitors
have no effect in the absence of such stimulation
Pharamacodynamics

5.
Absorption - Phosphodiesterase-5 Inhibitors are rapidly
absorbed from the gastrointestinal (GI) tract, with
maximal plasma concentrations reached in 30 to 120
minutes.Because it is lipophilic, concomitant ingestion of
a high-fat meal delays the rate of absorption
Excretion - Excretion of 80 percent of the dose is via
feces, and another 13 percent is eliminated in the urine.
Elimination is reduced in persons over age 65 years,
Elimination is also reduced in the presence of severe renal
or hepatic insufficiency.
Pharmacokinetics

6.
Half life -The mean half-lives of sildenafil and
vardenafil are 3 to 4 hours and that of tadalafil is
about 18 hours. Tadalafil can be detected in the
bloodstream 5 days after ingestion, and because
of its long half-life, it has been marketed as
effective for up to 36 hours.

8.
Pulmonary Hypertension –
Because PDE5 is also present in the arterial wall smooth
muscle within the lungs, PDE5 inhibitors have also been
explored for the treatment of pulmonary hypertension.
Sildenafil is more selective for pulmonary circultaion than
vardenafil, and is the only PDE 5 inhibitor shown to
improve arterial oxygenation in PAH

9.
Other Uses
Currently two more PDE-5 inhibitors, tadalafil and
vardenafil, are under study. Newer compounds have certain
advantages over sildenafil, including greater selectivity for
PDE-5 compared with other isoenzymes, absence of effect
of food on absorption, faster onset and longer duration of
action.

10.
PDE-5 inhibitors are emerging as novel therapeutic tools with
a potential to protect or enhance endothelial function in
humans and to selectively improve regional blood flow.The
FDA has recently approved a reformulation of sildenafil for the
treatment of Raynaud's phenomenon, respiratory disorders
with ventilation/perfusion mismatch, congestive cardiac
failure, hypertension and stroke are the other conditions in
which PDE-5 inhibitors are being tried.
Tadalafil

11.
Myocardial infraction The most important potential
adverse effect associated with use of these drugs is
myocardial infarction (MI). FDA distinguished the risk of
MI caused directly by these drugs from that caused by
underlying conditions, such as
hypertension, atherosclerotic heart disease, diabetes
mellitus, and other atherogenic conditions. Increased
oxygen demand and stress is placed on the cardiac
muscle by sexual intercourse, however.Thus, coronary
perfusion may be severely compromised and cardiac
failure may occur as a result.
Precautions and Adverse Reactions

12.
Non arteritic anterior ischemic optic neuropathy
Recently there have been 50 reports and 14 verfied cases
of a serious condition in men taking Sildenafil called non
arteritic anterior ischemic optic neuropathy (NAION).This
is an eye ailment that causes restriction of blood flow to
the optic nerve and can result in permanent vision loss.
The first symptoms appear within 24 hours after use of
Sildenafil and include blurred vision and some degree of
vision loss. The incidence of this effect is very rare. In the
reported cases, many patients had preexisting eye
problems which may have increased their risk.

13.
Common adverse effects- Headache, flushing, and
stomach pain.
Less common adverse effects - Nasal
congestion, urinary tract infection, abnormal
vision, increased sensitivity to light, or blurred
vision), diarrhea, dizziness, and rash.
Use of PDE-5 inhibitors is contraindicated in persons
who are taking organic nitrates in any form.The
combination of organic nitrates and PDE inhibitors can
cause a precipitous lowering of blood pressure (BP) and
can reduce coronary perfusion to the point of causing
MI and death.

14.
Sildenafil - Sildenafil is available as 25-, 50-, and 100-
mg tablets. The recommended dose of sildenafil is 50
mg taken by mouth 1 hour prior to intercourse. The
duration of the effect is usually 4 hours, Based on
effectiveness and adverse effects, the dose should be
titrated between 25 and 100 mg. Sildenafil is
recommended for use no more than once a day.
Vardenafil - Vardenafil is supplied in 2.5-, 5-, 10-, and
20-mg tablets. The initial dose is usually 10 mg taken
with or without food about 1 hour before sexual
activity. The dose can be increased to a maximum of 20
mg or decreased to 5 mg based on efficacy and side
effects.
Dosage and Clinical Guidelines

15.
Tadalafil -The recommended dose of tadalafil is 10 mg
before sexual activity, which may be increased to 20 mg
or decreased to 5 mg, depending on efficacy and side
effects. Because of its long half-life, it should probably
not be used more than once every 36 hours,

16.
The major route of PDE-5 metabolism is through CYP450
(CYP) 3A4, and the minor route is through CYP 2C9.
Inducers or inhibitors of these enzymes, therefore, will
affect the plasma concentration and half-life of sildenafil.
For example, 800 mg of cimetidine, a nonspecific CYP
inhibitor, increases plasma sildenafil concentrations by 56
percent,
Erythromycin (E-mycin) increases plasma sildenafil
concentrations by 182 percent.
Drug Interactions

17.
PDE 5 inhibitors are effective regardless of the baseline severity of
erectile dysfunction, race, or age.
 PDE 5 inhibitors increase cGMP to enhance erectile function
Sildenafil is more selective for pulmonary circultaion than
vardenafil, and is the only PDE 5 inhibitor shown to improve arterial
oxygenation in PAH
The most important potential adverse effect associated with use of
these drugs is myocardial infarction (MI).
Use of PDE-5 inhibitors is contraindicated in persons who are taking
organic nitrates
Sildenafil is recommended for use no more than once a day. Dosage
is between 25 mg 100mg
Summary